CBD drug manufacturer GW Pharmaceuticals saw a significant net loss in the last quarter, despite growth and sales of its cannabis-derived pharmaceutical drugs going to plan.
The company reported a loss of $71.9m for the quarter ending 31st December 2018, compared with $61.8m for the same quarter in 2017.
...15% OFF on our latest reports
Use the code CBD15OFF to apply the discount on the following available reports:
·
Interest booming in online CBD sales: Germany market report
· CBD in the UK: consumer choices and behaviours under the spotlight
· EU states could deem CBD, other cannabinoids illegal in cosmetics
· Cannabis to be legalised? Mexico regulatory report
*Offer available until 31st of Marchport.
Start your FREE trial version
Sign up to access to our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
